The incidence of mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) in de novo acute
myeloid leukemia (AML) is approximately 20%. These mutations result in distinct metabolic
characteristics including dependency of cancer cells on glutamine as the main source for α-
ketoglutarate, which is consumed by leukemia cells to produce a cancer-derived metabolite,
2-hydroxyglutarate. We sought to exploit this glutamine addiction therapeutically in mutant
IDH primary AML cells from patients by measuring cell growth after exposure to a small …